Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17 – 22, in San Diego, CA.
Boundless has identified a novel kinesin target (“Kinesin”) essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. Boundless is developing BBI-940, a potentially first-in-class, oral, selective, Kinesin degrader, which is the subject of the ongoing first-in-human KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology) clinical trial in patients with advanced or metastatic estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer or triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR).
Details of the presentation are as follows:
Title: Selective degradation of a novel kinesin as a potential therapeutic strategy addressing high-risk extrachromosomal DNA (ecDNA) positive cancers, including breast cancer
Abstract Presentation Number: LB361
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Tuesday, April 21, 2026, 2:00 PM - 5:00 PM PT
Location: Poster Section 53
Poster Board Number: 18
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class oral, selective, Kinesin degrader as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, CA.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Exchange Traded Funds Top 10 Volume Leaders
NET % VOL STOCK (Symbol) LAST CHG CHG 100s Direxion Semicon Br 3x SOXS 33.79 3.14 10.24 113,576,607 ProShares Bitcoin ETF BITO 10.93 -0.21 -1.89 112,012,221 Direxion Semicon Bl 3x SOXL 142.52 -16.39 -10.31 100,351,229 ProShares Sh Russell2001 RWM 14.43 0.01 0.07 77,482,048 GrShr 2x Sh NVDA Daily NVD 3.55 0.20 5.97 73,813,301 ProShares UltraPro QQQ TQQQ 80.23 -3.39 -4.05 65,485,124 ProSh UltraPro Shrt QQQ SQQQ 33.37 1.30 4.05 60,470,210 iShares Bitcoin Trust ETF IBIT 46.26 -0.95 -2.01 56,191,237 Direxion PLTR Bear 1X PLTD 4.50 -0.11 -2.39 52,552,250 SS Energy Sel SPDR XLE 65.24 1.88 2.97 50,492,628 (END) Dow Jones Newswires October 08, 2026 17:38 ET (21:38 GMT)
--Zoetis Keeps Quarterly Dividend at $0.53 a Share, Payable Dec. 1 to Holders of Record Oct. 30
04:46 PM EDT, 10/08/2026 (MT Newswires) -- Zoetis Keeps Quarterly Dividend at $0.53 a Share, Payable Dec. 1 to Holders of Record Oct. 30
Should You Buy Microsoft Stock (MSFT) in October? 3 Things Investors Need to Know
U.S. Fed weekly balance sheet
Oct 8 (Reuters) - For details of the Federal Reserve's balance sheet, see the following link: http://www.federalreserve.gov/releases/h41/Current/h41.pdf ((Washington newsroom))
Crypto prices
More
